GlobeNewswire Inc.··NaCervoMed's neflamapimod gains inclusion in UK's accelerated ALS clinical trial platform
CervoMed's neflamapimod selected for UK's accelerated EXPERTS-ALS trial platform. The drug will be evaluated in 35-80 ALS patients over 18-24 weeks.
CRVOclinical trialALS